Last reviewed · How we verify
Improvement of symptoms in patients with interstitial cystitis — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Rimso-50 | DIMETHYL SULFOXIDE | Mylan Institutional | dimethyl sulfoxide | 1978-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Mylan Institutional · 1 drug in Improvement of symptoms in patients with interstitial cystitis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Improvement of symptoms in patients with interstitial cystitis:
- Improvement of symptoms in patients with interstitial cystitis treatment updates — RSS
- Improvement of symptoms in patients with interstitial cystitis treatment updates — Atom
- Improvement of symptoms in patients with interstitial cystitis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Improvement of symptoms in patients with interstitial cystitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/improvement-of-symptoms-in-patients-with-interstitial-cystitis. Accessed 2026-06-10.
Related
- Improvement of symptoms in patients with interstitial cystitis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing